Cencora (COR) Q2 2025 Earnings
How Did COR Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +6.87%.
Did COR Beat Earnings? Q2 2025 Results
Yes. Cencora reported Q2 2025 earnings of $4.42 a share on May 7, 2025, beating the $4.10 consensus estimate by 7.9%. Revenue was $75.5B against a $75.8B estimate.
Cencora posted a solid fiscal second quarter, beating profit expectations comfortably while falling just short on the top line, as surging demand for specialty pharmaceuticals and GLP-1 products continued to power the business forward. Adjusted diluted EPS came in at $4.42, beating the $4.10 consensus estimate by 7.92% and rising 16.3% from the prior year, while revenue climbed 10.3% year-over-year to $75.45 billion, a fraction below the $75.80 billion analysts had expected. The U.S. Healthcare Solutions segment was the clear engine of growth, expanding 11.4% on the strength of specialty drug volumes, while the International segment offered little help, with operating income slipping 17.3% to $159.30 million amid weakness in global specialty logistics. The January acquisition of Retina Consultants of America, financed with roughly $3.30 billion in new debt, added meaningful gross profit contribution even as it had limited near-term revenue impact due to intercompany eliminations. Encouraged by U.S. earnings momentum, Cencora raised its full-year adjusted diluted EPS guidance to $15.70 to $15.95, up from $15.30 to $15.60 previously.
- Unit volume growth in overall pharmaceutical distribution market
- Increased sales of GLP-1 class products labeled for diabetes and/or weight loss
- Specialty product sales to physician practices and health systems
- January 2025 acquisition of Retina Consultants of America contributing to gross profit expansion
- Share repurchases reducing diluted shares outstanding by 3.0%
- Antitrust litigation settlement gains of $198.6 million
“Cencora's second quarter results reflect the strength of our value proposition as a healthcare services provider and the important role we play in the supply chain, driven by our pharmaceutical distribution footprint and complementary end-to-end services and solutions. We continue to advance our core business and enhance our capabilities, with a focus on elevating our solutions in the markets we serve.”
Cencora CEO, on the earnings call
What Was Cencora's Outlook in Q2 2025?
Cencora raised its fiscal year 2025 adjusted diluted EPS guidance to a range of $15.70 to $15.95, up from the previous range of $15.30 to $15.60, reflecting stronger U.S. Healthcare Solutions earnings growth and a lower contribution from the International segment. Updated expectations include: adjusted consolidated operating income growth of 13.5% to 15.5% (up from 11.5% to 13.5%); U.S. Healthcare Solutions segment operating income growth of 17.5% to 19.5% (up from 14.5% to 16.5%); International Healthcare Solutions segment revenue growth of 3% to 4% (down from 4% to 5%) with operating income expected to decline 1% to 4% (down from previous guidance of no growth); weighted average diluted shares outstanding of 195.0 to 195.5 million.
COR YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $75.5B | $68.4B | +10.3% |
| Gross Profit | $3.1B | $2.3B | +35.5% |
| Operating Income | $1.0B | $868.8M | +19.3% |
| Net Income | $717.9M | $420.8M | +70.6% |
COR Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.